It's an open label trial, so patients should be well-informed of all developments. Likewise, so is CTIX. But, public release of all information is controlled by Dana Farber and the PI. CTIX needs permission to release any information, including advancement of cohorts.
JB, being directly related to 2 cancer patients, they will definitely know as they live and die by whatever cancer marker apply's to their individual situation.
Market Data 
Markets 
AI
